Creso Pharma Limited

CPH

Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The firm cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. (Mernova) and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc. (Halucenex), it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

Hazer Group Limited

HZR

Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The principal activity of the Company is the research and development of hydrogen and graphitic carbon production technology. The Company’s advanced technology enables the production of clean and economically competitive hydrogen and graphite, using a natural gas (or biogas) feedstock and iron-ore as the process catalyst. The firm has intellectual property rights to a technology (the Hazer Process), which enables the production of hydrogen gas from the thermo-catalytic decomposition of methane (natural gas) with low carbon dioxide emissions and the co-production of a high-purity graphite product. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company has facilities, including a research and development lab and a fluid bed reactor pilot plant.

Mgc Pharmaceuticals Ltd

MXC

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

4Ds Memory Limited

4DS

4DS Memory Ltd. is a semiconductor development company, which engages in the provision of non-volatile memory technology, pioneering Interface switching ReRAM, for next generation gigabyte storage class memory in mobile and cloud. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-12-09. The firm is engaged in the development of a non-volatile memory technology, pioneering Interface Switching resistive random-access memory (ReRAM) for gigabyte storage in mobile and cloud. Interface Switching ReRAM, an area-based ReRAM technology positioned for Storage Class Memory in mobile devices and cloud data centers. The company owns a patented Internet protocol (IP) portfolio, comprising 34 United States patents granted, which has been developed in-house to create high-density storage class memory. The 4DS Interface Switching ReRAM meets the essential requirements for Storage Class Memory close to DRAM. The firm also collaborates with imec, a research and hub in nanoelectronics and digital technologies.